CLINICAL STUDIES
Effects of naloxone on myocardial ischemic preconditioning in humans
Fabrizio Tomai, MD, FACC*,
Filippo Crea, MD, FACC ,
Achille Gaspardone, MD, FACC*,
Francesco Versaci, MD, FACC*,
Anna S. Ghini, MD*,
Claudio Ferri, MD ,
Giovambattista Desideri, MD ,
Luigi Chiariello, MD, FACC* and
Pier A. Gioffré, MD*
* Divisione di Cardiochirurgia, Università di Roma Tor Vergata, European Hospital, Rome, Italy
Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome, Italy
Cattedra di Clinica Medica I, Università La Sapienza, Rome, Italy
Manuscript received October 15, 1998;
revised manuscript received January 25, 1999,
accepted February 15, 1999.
Reprint requests and correspondence: Dr. Fabrizio Tomai, Divisione di Cardiochirurgia, Università di Roma Tor Vergata, European Hospital, via Portuense 700, 00149 Rome, Italy
OBJECTIVES
We attempted to establish whether naloxone, an opioid receptor antagonist, abolishes the adaptation to ischemia observed in humans during coronary angioplasty after repeated balloon inflations.
BACKGROUND
Experimental studies indicate that myocardial opioid receptors are involved in ischemic preconditioning.
METHODS
Twenty patients undergoing angioplasty for an isolated stenosis of a major epicardial coronary artery were randomized to receive intravenous infusion of naloxone or placebo during the procedure. Intracoronary electrocardiogram and cardiac pain (using a 100-mm visual analog scale) were determined at the end of the first two balloon inflations. Average peak velocity in the contralateral coronary artery during balloon occlusion, an index of collateral recruitment, was also assessed by using a Doppler guide wire in the six patients of each group with a stenosis on the left anterior descending coronary artery.
RESULTS
In naloxone-treated patients, ST-segment changes and cardiac pain severity during the second inflation were similar to those observed during the first inflation (12 ± 6 vs. 11 ± 7 mm, p = 0.3, and 58 ± 13 vs. 56 ± 12 mm, p = 0.3, respectively), whereas in placebo-treated patients, they were significantly less (6 ± 3 vs. 13 ± 6 mm, p = 0.002 and 31 ± 21 vs. 55 ± 22 mm, p = 0.008, respectively). In both naloxone- and placebo-treated patients, average peak velocity significantly increased from baseline to the end of the first inflation (p = 0.04 and p = 0.02, respectively), but it did not show any further increase during the second inflation.
CONCLUSIONS
The adaptation to ischemia observed in humans after two sequential coronary balloon inflations is abolished by naloxone and is independent of collateral recruitment. Thus, it is due to ischemic preconditioning and is, at least partially, mediated by opioid receptors, suggesting their presence in the human heart.
|
Abbreviations and Acronyms
| | ECG | = electrocardiogram | | KATP channel | = adenosine triphosphatesensitive K+ channel | | PKC | = protein kinase C |
|
This article has been cited by other articles:

|
 |

|
 |
 
G. Niccoli, L. Altamura, A. Fabretti, G. A. Lanza, L. M. Biasucci, A. G. Rebuzzi, A. M. Leone, I. Porto, F. Burzotta, C. Trani, et al.
Ethanol Abolishes Ischemic Preconditioning in Humans
J. Am. Coll. Cardiol.,
January 22, 2008;
51(3):
271 - 275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Mentzer Jr, M. S. Jahania, and R. D. Lasley
Myocardial Protection
Card. Surg. Adult,
January 1, 2008;
3(2008):
443 - 464.
[Full Text]
|
 |
|

|
 |

|
 |
 
E. W. Dickson, C. P. Hogrefe, P. S. Ludwig, L. W. Ackermann, L. L. Stoll, and G. M. Denning
Exercise enhances myocardial ischemic tolerance via an opioid receptor-dependent mechanism
Am J Physiol Heart Circ Physiol,
January 1, 2008;
294(1):
H402 - H408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. R. Gross and G. J. Gross
Ligand triggers of classical preconditioning and postconditioning
Cardiovasc Res,
May 1, 2006;
70(2):
212 - 221.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Kloner and S. H. Rezkalla
Preconditioning, postconditioning and their application to clinical cardiology
Cardiovasc Res,
May 1, 2006;
70(2):
297 - 307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Michael. J. Watson, J. D. S. Holt, S. J. O'Neill, K. Wei, W. Pendergast, G. J. Gross, P. J. Gengo, and K.-J. Chang
ARD-353 [4-((2R,5S)-4-(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic Acid], A Novel Nonpeptide {delta} Receptor Agonist, Reduces Myocardial Infarct Size without Central Effects
J. Pharmacol. Exp. Ther.,
January 1, 2006;
316(1):
423 - 430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Argaud, G. Rioufol, M. Lievre, L. Bontemps, P. Legalery, M. Stumpf, G. Finet, R. Itti, X. Andre-Fouet, and M. Ovize
Preconditioning during coronary angioplasty: no influence of collateral perfusion or the size of the area at risk
Eur. Heart J.,
November 2, 2004;
25(22):
2019 - 2025.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.W. Broadhead, R.K. Kharbanda, M.J. Peters, and R.J. MacAllister
KATP Channel Activation Induces Ischemic Preconditioning of the Endothelium in Humans In Vivo
Circulation,
October 12, 2004;
110(15):
2077 - 2082.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Pepe, O. W.V van den Brink, E. G Lakatta, and R.-P. Xiao
Cross-talk of opioid peptide receptor and {beta}-adrenergic receptor signalling in the heart
Cardiovasc Res,
August 15, 2004;
63(3):
414 - 422.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T B Lindhardt, N Gadsboll, H Kelbaek, K Saunamaki, J K Madsen, P Clemmensen, B Hesse, and S Haunso
Pharmacological modulation of the ATP sensitive potassium channels during repeated coronary occlusions: no effect on myocardial ischaemia or function
Heart,
April 1, 2004;
90(4):
425 - 430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Zaugg, E. Lucchinetti, C. Garcia, T. Pasch, D. R. Spahn, and M. C. Schaub
Anaesthetics and cardiac preconditioning. Part II. Clinical implications
Br. J. Anaesth.,
October 1, 2003;
91(4):
566 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. YELLON and J. M. DOWNEY
Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology
Physiol Rev,
October 1, 2003;
83(4):
1113 - 1151.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Cao, L. Liu, and D. M. Van Winkle
Activation of {delta}- and {kappa}-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels
Am J Physiol Heart Circ Physiol,
August 7, 2003;
285(3):
H1032 - H1039.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Leesar, M. F. Stoddard, Y.-T. Xuan, X.-L. Tang, and R. Bolli
Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans
J. Am. Coll. Cardiol.,
August 6, 2003;
42(3):
437 - 445.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Mentzer Jr., M. S. Jahania, and R. D. Lasley
Myocardial Protection
Card. Surg. Adult,
January 1, 2003;
2(2003):
413 - 438.
[Full Text]
|
 |
|

|
 |

|
 |
 
R. M Fryer, J. A Auchampach, and G. J Gross
Therapeutic receptor targets of ischemic preconditioning
Cardiovasc Res,
August 15, 2002;
55(3):
520 - 525.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A Kloner, M. T Speakman, and K. Przyklenk
Ischemic preconditioning: a plea for rationally targeted clinical trials
Cardiovasc Res,
August 15, 2002;
55(3):
526 - 533.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Sigg, J. A. Coles Jr., P. R. Oeltgen, and P. A. Iaizzo
Role of delta -opioid receptor agonists on infarct size reduction in swine
Am J Physiol Heart Circ Physiol,
June 1, 2002;
282(6):
H1953 - H1960.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A D Kelion, T P Webb, M A Gardner, O J M Ormerod, G L Shepherd, and A P Banning
Does a selective adenosine A1 receptor agonist protect against exercise induced ischaemia in patients with coronary artery disease?
Heart,
February 1, 2002;
87(2):
115 - 120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Sigg, J. A. Coles Jr, W. J. Gallagher, P. R. Oeltgen, and P. A. Iaizzo
Opioid preconditioning: myocardial function and energy metabolism
Ann. Thorac. Surg.,
November 1, 2001;
72(5):
1576 - 1582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Heusch
Nitroglycerin and Delayed Preconditioning in Humans : Yet Another New Mechanism for an Old Drug?
Circulation,
June 19, 2001;
103(24):
2876 - 2878.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Schulz, P. Gres, and G. Heusch
Role of endogenous opioids in ischemic preconditioning but not in short-term hibernation in pigs
Am J Physiol Heart Circ Physiol,
May 1, 2001;
280(5):
H2175 - H2181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Fryer, Y. Wang, A. K. Hsu, and G. J. Gross
Essential activation of PKC-{delta} in opioid-initiated cardioprotection
Am J Physiol Heart Circ Physiol,
March 1, 2001;
280(3):
H1346 - H1353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Bell, M. N. Sack, A. Patel, L. H. Opie, and D. M. Yellon
Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle
J. Am. Coll. Cardiol.,
December 1, 2000;
36(7):
2296 - 2302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Yellon and A. Dana
The Preconditioning Phenomenon : A Tool for the Scientist or a Clinical Reality?
Circ. Res.,
September 29, 2000;
87(7):
543 - 550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Takasaki, R. A. Wolff, G. L. Chien, and D. M. van Winkle
Met5-enkephalin protects isolated adult rabbit cardiomyocytes via delta -opioid receptors
Am J Physiol Heart Circ Physiol,
December 1, 1999;
277(6):
H2442 - H2450.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|